Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Histological changes caused by meclofenamic acid in androgen-independent prostate cancer tumors: evaluation in a mouse model.

Delgado-Enciso I, Soriano-Hernández AD, Rodriguez-Hernandez A, Galvan-Salazar HR, Montes-Galindo DA, Martinez-Martinez R, Valdez-Velazquez LL, Gonzalez-Alvarez R, Espinoza-Gómez F, Newton-Sanchez OA, Lara-Esqueda A, Guzman-Esquivel J.

Int Braz J Urol. 2015 Sep-Oct;41(5):1002-7. doi: 10.1590/S1677-5538.IBJU.2013.00186.

2.

Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.

Hoare D, Skinner TA, Black A, Robert Siemens D.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):122-7. doi: 10.5489/cuaj.2545.

3.

Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation.

Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH.

J Cell Biochem. 2014 Sep;115(9):1505-15. doi: 10.1002/jcb.24805.

4.

Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression.

Hamilton G, Olszewski-Hamilton U, Theyer G.

Cancers (Basel). 2011 Sep 15;3(3):3601-9. doi: 10.3390/cancers3033601.

5.

Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy.

Theyer G, Holub S, Olszewski U, Hamilton G.

Open Access J Urol. 2010 Sep 7;2:155-9. doi: 10.2147/OAJU.S13046. eCollection 2010.

6.

EZH2, an epigenetic driver of prostate cancer.

Yang YA, Yu J.

Protein Cell. 2013 May;4(5):331-41. doi: 10.1007/s13238-013-2093-2. Epub 2013 Apr 30. Review.

7.

Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.

Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW.

PLoS One. 2013 Apr 9;8(4):e61064. doi: 10.1371/journal.pone.0061064. Print 2013.

8.

Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells.

Levine PM, Lee E, Greenfield A, Bonneau R, Logan SK, Garabedian MJ, Kirshenbaum K.

ACS Chem Biol. 2012 Oct 19;7(10):1693-701. doi: 10.1021/cb300332w. Epub 2012 Aug 7.

9.

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.

Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campennì GM, Palazzo A, Cortesi E.

Cancer Biol Ther. 2012 Sep;13(11):1001-8. doi: 10.4161/cbt.21188. Epub 2012 Jul 24. Review.

10.

Immunotherapy of cancer in 2012.

Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S.

CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. Review.

11.

Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.

Lack NA, Axerio-Cilies P, Tavassoli P, Han FQ, Chan KH, Feau C, LeBlanc E, Guns ET, Guy RK, Rennie PS, Cherkasov A.

J Med Chem. 2011 Dec 22;54(24):8563-73. doi: 10.1021/jm201098n. Epub 2011 Nov 18. Erratum in: J Med Chem. 2012 Jan 12;55(1):565.

12.

Castration-resistant prostate cancer: new science and therapeutic prospects.

Bellmunt J, Oh WK.

Ther Adv Med Oncol. 2010 May;2(3):189-207. doi: 10.1177/1758834009359769.

13.

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL.

Immunol Res. 2011 Aug;50(2-3):235-47. doi: 10.1007/s12026-011-8224-z.

14.

Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.

Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim YJ.

Clin Cancer Res. 2011 Jun 15;17(12):3984-92. doi: 10.1158/1078-0432.CCR-10-3262. Epub 2011 May 4.

15.

Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth.

Wolff DW, Xie Y, Deng C, Gatalica Z, Yang M, Wang B, Wang J, Lin MF, Abel PW, Tu Y.

Int J Cancer. 2012 Apr 1;130(7):1521-31. doi: 10.1002/ijc.26138. Epub 2011 Jun 9.

16.

PET/CT Imaging and Radioimmunotherapy of Prostate Cancer.

Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P.

Semin Nucl Med. 2011 Jan;41(1):29-44. doi: 10.1053/j.semnuclmed.2010.08.005. Review.

17.

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.

Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE.

Nat Med. 2010 Dec;16(12):1414-20. doi: 10.1038/nm.2236. Epub 2010 Nov 7.

18.

miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes.

Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW.

Prostate. 2011 Apr;71(5):538-49. doi: 10.1002/pros.21270. Epub 2010 Sep 30.

19.
20.

Redefining hormone resistance in prostate cancer.

Hoimes CJ, Kelly WK.

Ther Adv Med Oncol. 2010 Mar 1;2(2):107-123.

Supplemental Content

Support Center